Andrew Ortega, MD
Family Medicine · San Antonio, TXNPI 1225003122
Payments from drug & device makers
Across 144 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$329
- Johnson & Johnson$241
- Astellas Pharma US Inc$240
- AbbVie$233
- Amgen$205
- Bayer$153
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,36393%
- Education$1857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $329 |
| Johnson & Johnson(2 entities) | 14 | $241 |
| Astellas Pharma US Inc | 6 | $240 |
| AbbVie(2 entities) | 12 | $233 |
| Amgen | 11 | $205 |
| Bayer | 8 | $153 |
| Lilly USA, LLC | 8 | $138 |
| Abbott | 6 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $126 |
| Boehringer Ingelheim | 6 | $113 |
| Sumitomo Pharma America, Inc. | 6 | $98 |
| AstraZeneca(2 entities) | 6 | $97 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Novartis | 3 | $51 |
| GSK | 3 | $40 |
| Merck | 3 | $38 |
| Dynavax Technologies Corporation | 4 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $32 |
| Genentech USA, Inc. | 2 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$2,548 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $212,864 |
| OzempicSemaglutide | 153 | $168,695 |
| EliquisApixaban | 102 | $86,436 |
| JanuviaSitagliptin Phosphate | 49 | $74,286 |
| TrulicityDulaglutide | 46 | $65,740 |
| FarxigaDapagliflozin Propanediol | 38 | $60,390 |
| MounjaroTirzepatide | 47 | $59,213 |
| LinzessLinaclotide | 57 | $50,905 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $41,170 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $36,550 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $34,342 |
| MyrbetriqMirabegron | 45 | $33,353 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $31,626 |
| GemtesaVibegron | 35 | $30,765 |
| XareltoRivaroxaban | 19 | $28,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $113 | $303,559189 claims |
| Novo NordiskOzempic | $329 | $168,695153 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $138 | $124,95493 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $38 | $117,686101 claims |
| PfizerEliquis | $17 | $86,436102 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $97 | $77,61480 claims |
| AbbVieLinzess | $233 | $50,90557 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $40 | $37,76567 claims |
| Astellas Pharma US IncMyrbetriq | $240 | $33,35345 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $98 | $30,76535 claims |
| Johnson & JohnsonXarelto | $241 | $28,19119 claims |
| NovartisEntresto | $51 | $22,62321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.